Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 15/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608578 | 0.90 | PIK3CA (0.47) | PIK3CA | |
| SCHEMBL2123656 | 0.81 | PIK3CA (0.41) | PIK3CAGPR6 | |
| SCHEMBL17635535 | 0.79 | PIK3CA (0.41) | PIK3CA | |
| SCHEMBL2125290 | 0.78 | PIK3CA (0.47) | PIK3CA | |
| SCHEMBL2711122 | 0.78 | KDM4E (0.38) | PIK3CALMNA | |
| SCHEMBL2712128 | 0.77 | HRH4 (0.48) | PIK3CAHRH4 | |
| SCHEMBL2124095 | 0.77 | PIK3CA (0.52) | PIK3CALMNA | |
| SCHEMBL248736 | 0.76 | PIK3CA (0.54) | PIK3CALMNA | |
| SCHEMBL2711898 | 0.76 | PIK3CA (0.50) | PIK3CA | |
| SCHEMBL2713627 | 0.76 | PIK3CA (0.38) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 28/4885GPR6 1928/4885HRH4 881/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 29/4885GPR6 1782/4885HRH4 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.